WELDON STEVEN W (CFO) sold 8.8% of their position (396.30K shares) of GT BIOPHARMA, INC. on the open market
Open‑market sale worth $113.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−50K
Price / share
$0.25
Trade value
$12.50K
% of position
Common Stock
Shares
−50K
Price / share
$0.26
Trade value
$13K
% of position
Common Stock
Shares
−50K
Price / share
$0.28
Trade value
$14K
% of position
Common Stock
Shares
−50K
Price / share
$0.29
Trade value
$14.50K
% of position
Common Stock
Shares
−46.30K
Price / share
$0.29
Trade value
$13.43K
% of position
Common Stock
Shares
−50K
Price / share
$0.30
Trade value
$15K
% of position
Common Stock
Shares
−50K
Price / share
$0.30
Trade value
$15K
% of position
Common Stock
Shares
−50K
Price / share
$0.32
Trade value
$16K
% of position
Net shares
−396.30K
Net value
-$113.43K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/11/2020 | S · Sale | −50K | $0.25 | $12.50K | 1.1% | 4.50M | 4.45M |
| Common Stock Direct | 12/11/2020 | S · Sale | −50K | $0.26 | $13K | 1.1% | 4.45M | 4.40M |
| Common Stock Direct | 12/14/2020 | S · Sale | −50K | $0.28 | $14K | 1.1% | 4.40M | 4.35M |
| Common Stock Direct | 12/14/2020 | S · Sale | −50K | $0.29 | $14.50K | 1.1% | 4.35M | 4.30M |
| Common Stock Direct | 12/14/2020 | S · Sale | −46.30K | $0.29 | $13.43K | 1.1% | 4.30M | 4.25M |
| Common Stock Direct | 12/15/2020 | S · Sale | −50K | $0.30 | $15K | 1.2% | 4.25M | 4.20M |
| Common Stock Direct | 12/15/2020 | S · Sale | −50K | $0.30 | $15K | 1.2% | 4.20M | 4.15M |
| Common Stock Direct | 12/15/2020 | S · Sale | −50K | $0.32 | $16K | 1.2% | 4.15M | 4.10M |
| Total | −396.30K | -$113.43K | ||||||